Tianjin TEDA Receives Approval For Biopharma Development Plan
This article was originally published in PharmAsia News
Executive Summary
Tianjin Economic-Technological Development Area has received approval for its biopharmaceutical industry plan, which aims to cultivate biopharmaceuticals as its key industry through a 10-year development plan. By 2015, the industry's output value will reach RMB 50 billion, accounting for 5 percent of TEDA's total value. With more than 200 pharmaceutical enterprises setting up bases, the development area seeks to be an influential drug R&D and manufacturing hub in Asia Pacific by participating in the international industry. TEDA will provide assurances and support for the biopharma sector in eight aspects, namely, system, space, funds, talent, policy, technology, services and resources. (Click here for more - Chinese language)
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.